Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

Mingxing HOU 1, *Haiqing HU 2, Chunlu JIN 2, Xuemei YU 2

1. Department of Gastroenterology Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, 010058, China
2. Department of Gastroenterology and Hepatology Chinese PLA General Hospital, Beijing, 100853, China

*Corresponding Author: Email: huhaiqignm@163.com
(Received 11 Mar 2019; accepted 25 May 2019)

Abstract

Background: We investigated the efficacy of esomeprazole for the treatment of gastroesophageal reflux disease (GERD) in a meta-analysis of clinical trials results.

Methods: Medline, Embase, PubMed and Web of Science databases were systematically searched for suitable studies, and double-blind, randomized controlled trials (RCTs) were involved. A meta-analysis of RCTs was performed to analyze the efficacy of esomeprazole on clinical outcomes that associated with the severity of GERD.

Results: A total of 8 clinical trials were selected in our meta-analysis (N=4495, patients with GERD). Esomeprazole treatment yielded a significant improvement in clinical signs and symptoms of GERD compared to placebo group. Funnel plot and Egger test showed there was no significant bias in the publication. Cochrane collaboration tool and Jadad scale were used to indicate that all 8 RCTs were of high quality. The results of Galbraith radial plot showed that no study was the major source of heterogeneity. Esomeprazole treatment significantly decreased the relapse rates more than that of placebo group (RR = 0.729; 95% CI: 0.670 to 0.794; P<0.001). It seems to be lower rates of heartburn (RR = 0.747; 95%CI: 0.665-0.839; P<0.001) and epigastric pain (RR = 0.795; 95%CI: 0.679-0.932; P=0.005) in esomeprazole-treated group compared with the placebo group. Moreover, serious adverse events was less likely to happen after esomeprazole therapy (RR = 1.406, 95% CI: 1.030-1.918; P=0.032).

Conclusion: Compared with the control group, esomeprazole is a promising therapeutic agent that improves the management of patients with GERD.

Keywords: Esomeprazole; Meta-analysis; Gastroesophageal reflux disease; Clinical efficacy; Safety

Introduction

Gastroesophageal reflux disease (GERD) is defined by esophageal and extraesophageal syndromes caused by the reflux of gastric contents (1-3). It is acceptable that symptoms induced by GERD seem to be more common now than 25 yr ago (4-6). GERD is prevalent worldwide with prevalence estimates showing greatest prevalence in North America (19.8%) and lowest in East Asia (5.2%) (7-10).

Acid suppression is recognized as the mainstay of treatment for GERD, and proton pump inhibitors (PPIs) therapy traditionally served as the
most rapid symptomatic relief in majority of patients (11-13). Recently, five PPIs were available for treating GERD, including omeprazole, pantoprazole, lansoprazole, rabeprazole and esomeprazole (14-18). Esomeprazole, as the isomer of omeprazole, has been developed and marketed with less adverse events compared with omeprazole (19, 20). All the PPIs are racemates, which leads to pharmacologically differences caused by their spatial disposition (21-23). Previous study was designed and suggested modest benefits of one drug over another (24-26). The efficacy of esomeprazole in patients with GERD symptoms control, include heartburn, acid regurgitation, dysphagia, and epigastric pain, remains controversial compared with other acid suppression drugs (27-32). Previous meta-analysis has been designed and suggests similar healing rates and relapse rates of omeprazole treatment compared with three other developed PPI drugs (pan- toprazole, lansoprazole, rabeprazole) however not included esomeprazole (24).

We analyzed the efficacy of esomeprazole for GERD treatment in a meta-analysis of clinical trial results.

Methods

This meta-analysis was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta Analyses) statement as a guideline (http://www.prisma-statement.org/).

Search strategy and inclusion criteria

On Nov 1st 2017, we conducted a systematic search of PubMed, Medline, Embase, and Web of Science databases for randomized controlled trials (published between Nov 1, 2000 and Nov 1, 2017; English publication only) using the search terms “esomeprazole” and “gastroesophageal reflux disease”. All the enrolled studies using the strategy were checked independently by 2 authors; additionally, the articles that met all inclusion criteria were enrolled in this meta-analysis. The inclusion criteria were as follows: 1) patients were diagnosed of GERD and treated with esomeprazole; 2) double-blind, randomized, placebo-controlled studies; 3) outcome measures including relapse rate, heartburn rate and epigastric pain rate.

Testing for heterogeneity, risk of bias and sensitivity Meta-analysis

Q test and I² test were performed to analysis the heterogeneity of the studies that included in this meta-analysis. The Galbraith radial plot was made to indicate the cause of heterogeneity in studies using STATA 12.0 software. Each study was represented as a single dot with a central regression line through the plot. Moreover, Cochrane collaboration tool was used to evaluate the qualities of the included studies and the risk of bias, and the Egger test was performed which is a linear regression method to evaluate the bias in publication in our meta-analysis. Sensitivity analysis was described using STATA 12.0 software.

Data extraction and outcomes

In our systematic review, the following variables were extracted: study, year, country, ages of esomeprazole/placebo group, numbers of esomeprazole-treated patients and control subjects, study type, name of the study, clinicaltrials.gov number, esomeprazole doses used, duration of study periods and outcomes.

Statistical Meta-analysis

From the included studies in the analysis, we extracted for esomeprazole and placebo relapse rates, heartburn rates and epigastric pain rates (along with the corresponding 95% CI). The overall summary effect sizes were estimated using a random-effects model if heterogeneity was over 50% and fixed-effects model was used if heterogeneity was under 50%. The quantitative data was expressed as standardized mean difference (SMD), and numeration data was presented as relative risk (RR). Data was expressed as mean (range) or mean±SD, and a P value of < 0.05 was considered to be statistically significant. Forest plots and data analysis were performed using Review Manager (RevMan version 5.3; Nordic Cochrane Centre, Copenhagen, Denmark) and
Results

Study selection
The systematic search terms identified 791 original articles and the flow diagram of the studies was showed in Fig. 1. A total of 348 duplicates and 402 irrelevant articles were excluded, and 33 abstracts were removed as they did not meet the inclusion criteria in this meta-analysis. Finally, 8 RCTs were included for our meta-analysis (33-40). All 8 clinical trials are randomized controlled studies. All were published in English.

Study characterization
The characteristics of the included RCTs are shown in Table 1. Three studies (33, 35, 40) were performed only in US, and other studies involved in different countries. All the studies were followed up 6 months and all the dosage of the esomeprazole was 20 mg/d. However, the drugs in the control group varied. All of the 8 trials were randomized, double-blinded, and placebo controlled trials.

Risk of bias, sensitivity analysis and quality assessment
Funnel plot was made to describe the bias in publications (Fig. 2). All of 8 RCTs enrolled in this meta-analysis unfolded a low risk of bias. Cochrane collaboration tool was used to show the risk of bias of 8 RCTs shown in Fig. 3. They all applied random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment and had low risk of incomplete outcome data and selective reporting.
**Table 1:** Characteristics of the included RCTs

| Study       | Study type | Country                      | Follow up | N (M/F)    | Esomeprazole Age, years | Administration | N (M/F) | Control Age, years | Administration |
|-------------|------------|------------------------------|-----------|------------|--------------------------|----------------|---------|-------------------|----------------|
| Devault 2006 (33) | RCT        | US                           | 6 months  | 501 (297/204) | 47.5 (18-75) | 20 mg/d | 500 (293/207) | 47.9 (18-78) | Lan: 15 mg/d |
| Goh 2007 (34)     | RCT        | multi-countries              | 6 months  | 667 (396/271) | 48.8±14.5 | 20 mg/d | 636 (373/263) | 49.0±14.1 | Pan: 20 mg/d |
| Johnson 2001 (35) | RCT        | US                           | 6 months  | 82 (51/31)  | 46.3 (21-81) | 20 mg/d | 82 (48/34)  | 46.9 (19-73) | Eso: 40 mg/d |
| Labenz 2005 (36)  | RCT        | multi-countries              | 6 months  | 1377 (888/489) | 50.2±14.1 | 20 mg/d | 1389 (856/533) | 50.7±13.8 | Pan: 20 mg/d |
| Lauritsen 2003 (37) | RCT       | Europe and South Africa      | 6 months  | 615 (388/227) | 4 (1-9)   | 20 mg/d | 609 (356/243) | 4 (1-9)   | Lan: 15 mg/d |
| Talley 2001 (38)  | RCT        | Denmark, Fenland, Norway and Sweden | 6 months | 170 (94/76)  | 49 (19-78) | 20 mg/d | 172 (98/74) | 49 (21-79) | placebo |
| Talley 2002 (39)  | RCT        | UK, Ireland and Canada       | 6 months  | 282 (135/147) | 4 (8-18)  | 20 mg/d | 293 (135/158) | 4 (8-18)  | Eso: 40 mg on demand |
| Vakil 2001 (40)   | RCT        | US                           | 6 months  | 92 (51/41)  | 47.1 (18-84) | 20 mg/d | 98 (58/40)  | 45.2 (19-76) | Eso: 40 mg/d |

All the RCTs were double-blinded: study subjects and investigators were both blinded. The clinical outcome data in the included studies were based on specific guideline, and their baselines were similar. Funnel plot and Egger test showed there was no significant bias in the publication (Fig. 4). Sensitivity analysis plot was performed to analyze the sensitivity of the included trials of this meta-analysis, indicating the stable results. The study qualities of each RCT were evaluated using the Jadad scale, and all 8 studies were of high quality. All 8 randomized controlled trials reported adequate randomization, and no RCT was stopped early. Jadad scale showed the study qualities of each randomized control trial (Table 2).

**Fig. 2:** Risk of publication bias for each trial. Both the funnel plot and Egger test showed no significant evidence of bias in the publication

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
Fig. 3: Risk of bias assessment. The qualities of the included studies were evaluated using Cochrane collaboration tool, indicating that there is no significant risk of bias in the included trials of this meta-analysis.

Fig. 4: Forest plot of the 8 RCT studies. (A) relapse rates; (B) heartburn; (C) acid regurgitation; (D) epigastric pain. Black dots represent the standardized mean difference (SMD), and Horizontal lines represent 95% CIs of the SMD estimates. Diamonds stand for summary effect estimate of the meta-analysis.
Table 2: The study qualities of each RCT were evaluated using the Jadad scale

| Reference | Year | Representation of randomization | Appropriateness of method for randomization | Representation of double blind | Appropriateness of method for double blind | Representation of withdrawals | Total score |
|-----------|------|---------------------------------|---------------------------------------------|-----------------------------|------------------------------------------|-----------------------------|-------------|
| Devault   | 2006 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |
| Goh       | 2007 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |
| Johnson   | 2001 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |
| Labenz    | 2005 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |
| Lauritsen | 2003 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |
| Talley    | 2001 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |
| Talley    | 2002 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |
| Vakil     | 2001 | 1                               | 1                                           | 1                           | 1                                        | 1                           | 5           |

**Efficacy outcomes of esomeprazole**

In a pooled analysis of all 8 RCTs, significant improvement of efficacy of esomeprazole was observed in various clinical indexes: relapse rates, heartburn, acid regurgitation and epigastric pain.

Four studies (33, 34, 36, 37) reported the relapse rates for esomeprazole treatment during six months. Heterogeneity test results showed that there was significant heterogeneity across individual studies ($P=0.046, I^2 = 42.6\%$). Therefore, the random effects model was selected to pool RR from individual studies. Fig. 3A shows that esomeprazole treatment had better curative effects than treatment with other drugs (risk ratio (RR) = 0.73; 95% confidence interval (CI): 0.67-0.79; $P<0.001$).

Five articles (33, 35, 37, 38, 40) reported heartburn symptoms of GERD reoccurrence after esomeprazole treatment. Significant heterogeneity between the studies ($P<0.001, I^2 = 78.3\%$) was found. When we pooled data from the 5 studies, esomeprazole showed better a curative effect on heartburn compared with other treatments using random effects model (RR = 0.75; 95% CI: 0.67-0.84; $P<0.001$) (Fig. 3B).

Two articles (33, 37) reported acid regurgitation symptom reoccurrence after esomeprazole treatment. According to the results of the heterogeneity test, heterogeneity across individual studies was found with statistical significance ($P=0.019, I^2 = 81.9\%$). When data from the studies were pooled using the random effects model, results showed no significant difference on acid regurgitation occurrence between esomeprazole treatment and other drug treatment (RR = 0.80, 95% CI: 0.68-0.93; $P=0.005$) (Fig. 3C).

Abdominal pain reoccurrence after esomeprazole treatment was reported in two papers (33, 37). Lower abdominal pain occurrence after esomeprazole treatment compared with other esomeprazole treatment was found using the fixed effect model (heterogeneity, $P>0.05$, $I^2=0\%$; RR=0.85, 95% CI: 0.72-1.00; $P=0.058$) (Fig. 3D).

**Safety**

Adverse events occurrence is a key indicator for evaluating drug treatment (41). Here, we compared adverse events and serious adverse events during six months maintenance treatment between esomeprazole group and control group. Adverse events were reported in 6 studies. Fig. 5A shows no significant difference between esomeprazole treatment and other drug treatment on adverse events occurrence (RR = 1.07, 95% CI: 1.00-1.15; $P=0.068$), and no significant heterogeneity was found across studies ($P=0.21, I^2 = 30.1\%$).

Seven articles reported serious adverse events. As shown in Fig. 5B, we pooled data from the studies and found higher serious adverse events risk after other drug treatment than esomeprazole treatment (RR = 1.41, 95% CI: 1.03-1.92; $P=$

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
0.032) without significant heterogeneity ($P = 0.61$, $I^2 = 0\%$).

**Test of heterogeneity**

We generated to identify potential sources of heterogeneity of overall effects based on the forest plots, we discovered that the heartburn and acid regurgitation symptom can significantly affect the heterogeneity of outcome result; meanwhile, relapse rates and abdominal pain recurrence may not contribute to the data heterogeneity. To explore the source of heterogeneity, Galbraith radial plot was performed. No study was the major source of heterogeneity (Fig. 6).

![Forest plot of the adverse events and serious adverse events of esomeprazole.](image)

**Fig. 5:** Forest plot of the adverse events and serious adverse events of esomeprazole. (A) adverse events; (B) serious adverse events. Black dots represent the standardized mean difference (SMD), and horizontal lines represent 95% CIs of the SMD estimates. Diamonds stand for summary effect estimate of the meta-analysis.
Hou et al.: Efficacy and Safety of Esomeprazole for the Treatment of Reflux

Fig. 6: Galbraith radial plot. The figures show the contribution of results from the different studies to the heterogeneity. No study was shown to be the main source of the heterogeneity

Discussion

In this meta-analysis, our results demonstrated the efficacy and safety of esomeprazole in the treatment of patients with GERD across 8 RCTs. Esomeprazole was shown to be consistently more effective than placebo and has a placebo-like safety profile. This is the newest systematic analysis and comparison of all double-blinded RCT’s data for the treatment of GERD. The trials included have high consistency in the patients enrolled, randomization and masking, and treatment outcomes. The endpoints these clinical trials applied include objective indexes, subjective indexes, or both, which provide comprehensive assessment of the treatment responses. Relapse rates is objective assessment of the disease severity, whereas heartburn, acid regurgitation and epigastric pain combined both objective and subjective evaluation of GERD (42-45). The 8 trials included in this review are consistent in applying the similar objective and subjective clinical index, and the results from 8 trials are also consistent in that esomeprazole are effective and safe in the treatment of GERD, as evidenced not only by decreased symptoms of gastroesophageal reflux recurrence, but also by decreased side events occurrence.

The RCTs with esomeprazole did not show serious adverse events. Further clinical trials would provide more information on this issue. Overall, esomeprazole is a promising therapeutic agent that improves the management of patients with GERD. Most importantly, the esomeprazole treatment is very safe.

A limitation of this meta-analysis is the limited number of clinical trials (only 8) included in this study. However, all the trials were double-blinded, randomized, and placebo-controlled studies; therefore, they are of high quality. Furthermore, although almost all publications included in this study were from top journals with high impact factors, risks of bias e.g. funding from pharmaceutical industry may exist. Because of the restriction of ethics, it’s not easy to carry out clinical trials in the population of children, which are the special population of GERD, and future study should address the potential application of esomeprazole in this population.

PPI drugs are still recommended by the current guidelines for the treatment of GERD when topical treatment or phototherapy is ineffective; however, the frequently occurring serious adverse events hinders the use of systemic anti-GERD treatment (45-50). Our finding clearly indicates that esomeprazole is a promising anti-GERD
medication, and would meet the need of treating GERD specifically and efficiently. Further investigations should prove the long-term stability, efficacy, and safety of esomeprazole in treating GERD.

Conclusion

Esomeprazole is a promising therapeutic agent that improves the management of patients with GERD without serious adverse effects.

Ethical considerations

Ethical issues (including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

This work was funded by grants from Application Technology Research and Development Project in health field of Inner Mongolia Autonomous Region (201802160).

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Clarke JO, Fernandez-Becker NQ, Regalia KA, Triadafilopoulos G (2018). Baclofen and gastroesophageal reflux disease: seeing the forest through the trees. Clin Transl Gastroenterol, 9 (3):137.
2. Kellerman R, Kintanar T (2017). Gastroesophageal Reflux Disease. Prim Care, 44 (4):561-573.
3. Barnhart DC (2016). Gastroesophageal reflux disease in children. Semin Pediatr Surg, 25 (4):212-8.
4. Maqbool A, Ryan MJ (2018). Gastroesophageal Reflux Disease and Aerodigestive Disorders.
5. Patti MG (2016). An Evidence-Based Approach to the Treatment of Gastroesophageal Reflux Disease. JAMA Surg, 151 (1):73-8.
6. Mikami DJ, Murayama KM (2015). Physiology and pathogenesis of gastroesophageal reflux disease. Surg Clin North Am, 95 (3):515-25.
7. Quach DT, Nguyen TT, Hiyama T (2018). Abnormal Gastroesophageal Flap Valve Is Associated With High Gastroesophageal Reflux Disease Questionnaire Score and the Severity of Gastroesophageal Reflux Disease in Vietnamese Patients With Upper Gastrointestinal Symptoms. J Neurogastroenterol Motil, 24 (2):226-232.
8. Surdea-Blaga T, Negruțiu DE, Palage M, Dumitrescu DL (2019). Food and Gastroesophageal Reflux Disease. Curr Med Chem, 26 (19):3497-3511.
9. Kethman W, Hawn M (2017). New Approaches to Gastroesophageal Reflux Disease. J Gastrointest Surg, 21 (9):1544-1552.
10. Chen J, Brady P (2019). Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment. Gastroenterol Nurs, 42 (1):20-28.
11. Mermelstein J, Chait Mermelstein A, Chait MM (2018). Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol, 11:119-134.
12. Yadlapati R, DeLay K (2019). Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Med Clin North Am, 103 (1):15-27.
13. Katz PO, Gerson LB, Vela MF (2013). Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol, 108 (3):308-28.
14. Sandhu DS, Fass R (2018). Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver, 12 (1):7-16.
15. Gyawali CP, Fass R (2018). Management of Gastroesophageal Reflux Disease. Gastroenterology, 154 (2):302-318.
16. Delshad SD, Almario CV, Chey WD, Spiegel BMR (2020). Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology, 158 (5):1250-1261.e2.
17. Gyawali CP (2017). Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep, 19 (9):46.
18. Miyazaki H, Igarashi A, Takeuchi T, et al (2019). Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. *J Gastroenterol Hepatol*, 34 (8):1316-1328.

19. Çelebi A, Aydin D, Koçaman O, et al (2016). Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease. *Türk J Gastroenterol*, 27 (5):408-414.

20. Sakurai K, Suda H, Fujie S, et al (2019). Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan. *Dig Dis Sci*, 64 (3):815-822.

21. Czinn SJ, Blanchard S (2013). Gastroesophageal reflux disease in neonates and infants: when and how to treat. *Paediatr Drugs*, 15 (1):19-27.

22. Qi Q, Wang R, Liu I, Zhao F, Wang S (2015). Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastroesophageal reflux disease: A systematic review and meta-analysis. *Int J Clin Pharmacol Ther*, 53 (10):803-10.

23. Chiанг HH, Wu DC, Hsu PI, et al (2019). Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. *Drug Des Devel Ther*, 13:1347-1356.

24. Kinoshita Y, Ishimura N, Ishihara S (2018). Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. *J Neurogastroenterol Motil*, 24 (2):182-196.

25. Liang CM, Kuo MT, Hsu PI, et al (2017). First-week clinical responses to dexlansoprazole 60 mg andesomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. *World J Gastroenterol*, 23 (47):8395-8404.

26. Davidson G, Wenzl TG, Thomson M, et al (2013). Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. *J Pediatr*, 163 (3):692-8.e1-2.

27. Hillman I, Yadlapati R, Thuluvath AJ, et al (2017). A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. *Dis Esophagus*, 30 (9):1-15.

28. Yu YY, Fang DC, Fan LL, et al (2014). Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders. *J Gastroenterol Hepatol*, 29 (6):1200-6.

29. Zacuto AC, Marks SL, Osborn J, et al (2012). The influence of esomeprazole and cisapride on gastroesophageal reflux during anesthesia in dogs. *J Vet Intern Med*, 26 (3):518-25.

30. Alzubaidi M, Gabbard S (2015). GERD: Diagnosing and treating the burn. *Clin Clin J Med*, 82(10):685-92.

31. Spechler SJ (2019). Proton Pump Inhibitors: What the Internist Needs to Know. *Med Clin North Am*, 103(1):1-14.

32. Hatlebakk JG, Zerbib F, Bruley des Varannes S, et al (2016). Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy. *Clin Gastroenterol Hepatol*, 14 (5):678-85.e3.

33. Devault KR, Johanson JF, Johnson DA, et al (2006). Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. *Clin Gastroenterol Hepatol*, 4 (7):852-9.

34. Goh KL, Benamouzig R, Sander P, Schwan T (2007). Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. *Eur J Gastroenterol Hepatol*, 19 (3):205-11.

35. Johnson DA, Benjamin SB, Vakil NB, et al (2001). Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. *Am J Gastroenterol*, 96 (1):27-34.

36. Labenz J, Armstrong D, Lauritsen K, et al (2005). Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive esophagitis: results from the EXPO study. *Aliment Pharmacol Ther*, 22 (9):803-11.

37. Lauritsen K, Devière J, Bigard MA, et al (2003). Esomeprazole 20 mg and lansoprazole 15 mg
in maintaining healed reflux oesophagitis: Metropole study results. *Aliment Pharmacol Ther*, 17 (3):333-41.
38. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al (2001). Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. *Aliment Pharmacol Ther*, 15 (3):347-54.
39. Talley NJ, Venables TL, Green JR, et al (2002). Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. *Eur J Gastroenterol Hepatol*, 14 (8):857-63.
40. Vakil NB, Shaker R, Johnson DA, et al (2001). The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. *Aliment Pharmacol Ther*, 15 (7):927-35.
41. Gilger MA, Tolia V, Vandenplas Y, et al (2015). Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease. *J Pediatr Gastroenterol Nutr*, 60 Suppl 1:S16-23.
42. Mei J, Yu Y, Ma J, Yu X (2016). Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms: a meta-analysis. *Pharmazie*, 71 (5):285-91.
43. Takeshima F, Hashiguchi K, Onitsuka Y, et al (2015). Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life. *Med Sci Monit*, 21:4111-21.
44. Cardile S, Romano C (2012). Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients. *Adolesc Health Med Ther*, 3:27-31.
45. Petryszyn P, Staniak A, Grzegorzka J (2016). Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland? *J Comp Eff Res*, 5 (2):169-78.
46. Tang RS, Wu JC (2013). Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients—focus on esomeprazole. *Clin Interv Aging*, 8:1433-43.
47. Richter JE, Kahrilas PJ, Johanson J, et al (2001). Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: randomized controlled trial. *Am J Gastroenterol*, 96 (3):656-65.
48. Namikoshi T, Harada K, Hatta H, et al (2016). Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis. *Clin Exp Nephrol*, 20 (1):134-42.
49. Goirand F, Le Ray I, Bardou M (2014). Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease. *Expert Opin Drug Metab Toxicol*, 10 (9):1301-11.
50. Earp JC, Mehrotra N, Peters KE, et al (2017). Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response. *J Pediatr Gastroenterol Nutr*, 65 (3):272-277.